Design early phase drug combination trials: methods

Published on May 29, 2017   29 min

Other Talks in the Series: Adaptive Clinical Trial Design

0:00
Hello. My name is Ying Yuan. I'm a professor in Biostatistics at MD Anderson Cancer Center. Today I'm going to talk about how to design early phase drug combination trial.
0:11
So here is outline of the talk. First, I will talk about the challenges for designing drug combination trials then I will talk about some specific designs for drug combination trial, specifically, I will talk about how to design a trial to find a single MTD, and how to design a trial to find its MTD contour. Then I will introduce some software to implement those designs, and I will finish the talk with a summary statement.
0:38
As we know, the primary objective of phase I trial is to find its maximum tolerated dose, which is defined as a dose with a specific targeted toxicity rate like 30%. So for single-agent trials, the standard assumption is that toxicity monotonically increases with the dose. So in this case, we only find a dose with a specific target toxicity rate.
Hide

Design early phase drug combination trials: methods

Embed in course/own notes